<?xml version="1.0" encoding="UTF-8"?><BillSummaries>
<item congress="116" measure-type="hr" measure-number="4398" measure-id="id116hr4398" originChamber="HOUSE" orig-publish-date="2019-09-19" update-date="2021-03-19">
<title>Affordable Prescriptions for Patients Through Promoting Competition Act of 2019</title>
<summary summary-id="id116hr4398v00" currentChamber="HOUSE" update-date="2021-03-19">
<action-date>2019-09-19</action-date>
<action-desc>Introduced in House</action-desc>
<summary-text><![CDATA[<p><b>Affordable Prescriptions for Patients Through Promoting Competition Act of 2019</b><br> <br> This bill prohibits product hopping by drug manufacturers. Product hopping is presumed when a drug manufacturer engages is a <i>hard switch</i> or a <i>soft switch</i>. A hard switch occurs when, after a manufacturer receives notice of an application for a generic drugs, either, (1) the manufacturer obtains removal of a drug from the Food and Drug Administration&rsquo;s approved drug list or the drug is moved to the discontinued products list, and the manufacturer markets or sells a follow-on product; or (2) a manufacturer announces the withdrawal or discontinuance of a listed drug, or the manufacturer destroys the inventory of a listed drug in a manner that impedes generic drug competitors, and the manufacturer markets or sells a follow-on product. A<i> follow-on product </i>is a changed, modified, or reformulated version of a manufacturer&rsquo;s already-approved drug or biological product that still treats the same medical condition.<br> <br> A soft switch occurs when a manufacturer receives notice of an application for a generic drugs, takes other actions that impede generic drug competitors, and the manufacturer markets or sells a follow-on product.<br> <br> A drug manufacturer may rebut a presumption of product hopping by demonstrating that its conduct was not intended to limit competition.<br> </p>]]></summary-text>
</summary>
</item>
<dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
<dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
<dc:description>This file contains bill summaries for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
</dublinCore>
</BillSummaries>
